Clinical Trial Update: Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

Kintara Therapeutics completed a Phase 1/2 safety study of VAL-083 in patients with recurrent malignant glioma, including glioma and glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• VAL-083 (dianhydrogalactitol)

Snippet

Sponsor: Kintara Therapeutics, Inc. | Conditions: Glioma, Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED